中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (12): 862-865.doi: 10.12144/zgmfskin202412862

• 临床研究 • 上一篇    下一篇

乌帕替尼治疗SAPHO综合征五例并文献复习

施晓军1*,李樱子1*,王露盈1,曹凤娇1,侯秀娟1,李忱2   

  1. 1北京中医药大学东方医院 北京中医药大学东方医院风湿科，北京，100078；2北京中医药大学房山医院 北京中医药大学房山医院风湿科，北京，102401 *共同第一作者
  • 出版日期:2024-12-15 发布日期:2024-10-31

Upadacitinib in the treatment of SAPHO syndrome: five cases report and literature review

SHI Xiaojun1*, LI Yingzi1*, WANG Luying1, CAO Fengjiao1, HOU Xiujuan1, LI Chen2   

  1. 1 Department of Rheumatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China; 2 Department of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing 102401, China * Co-first author
  • Online:2024-12-15 Published:2024-10-31

PDF (PC)

57

摘要： 目的：评价乌帕替尼治疗SAPHO综合征的疗效及安全性。方法：回顾性分析我院5例经乌帕替尼治疗的SAPHO综合征患者的临床资料。结果：5例患者均为掌跖脓疱病伴关节炎，其中2例指甲脱落，经司库奇尤单抗、依奇珠单抗、巴瑞替尼治疗无效，改用乌帕替尼治疗后皮损及骨痛症状缓解，无不良反应发生。结论：乌帕替尼可作为治疗SAPHO综合征的一种选择，尤其对多种生物制剂治疗无效的SAPHO综合征。

关键词: SAPHO综合征, 乌帕替尼, JAK抑制剂, 掌跖脓疱病

Abstract: Objective: To evaluate the safety and efficacy of upadacitinib in patients with SAPHO syndrome. Methods: The clinical data of five patients with SAPHO syndrome treated effectively with upadacitinib from January 2021 to June 2023 were retrospectively analyzed. Results: All five patients reported in this paper suffered from palmoplantar pustulosis with arthritic involvement with two presenting with nail loss. All had previously been ineffectively treated with NSAIDs, DMARDs, bisphosphonates, biologics or baricitinib. After switching to treatment with upadacitinib, patients experienced relief of skin lesions and bone pain, and no data of adverse events were found. Conclusions: Upatinib may be an option for the treatment of SAPHO syndrome, especially in cases where treatment with multiple biologics has failed.

Key words: SAPHO syndrome, upadacitinib, JAK inhibitor, palmoplantar pustulosis